This indefinite delivery contract (IDC) was awarded by the Centers for Disease Control and Prevention (CDC), National Center for Immunization and Respiratory Diseases (NCIRD) to AstraZeneca Pharmaceuticals LP for the procurement of adult influenza vaccines for the 2022-2023 flu season. The contract has a ceiling value of $12,337,500.00 and a period of performance from the date of award on January 5, 2022 through February 28, 2023.
The contract aims to procure a minimum of 100 doses and a maximum of 20 million doses of FDA-licensed, cGMP-manufactured inactivated influenza vaccines for individuals aged 19 years and older. Vaccines must be delivered FOB destination to CDC distribution centers in Aurora, Colorado and Memphis, Tennessee, as well as potential deliveries to five CDC occupational health clinics. This acquisition is being conducted under FAR Part 12, Acquisition of Commercial Items, in conjunction with FAR Part 15. There was no set-aside designation used for this single-award IDC.
Generated 12/18/24, 9:05 AM